Home › Filings & Releases › August 2026
Filings & Releases — August 2026
1,069 documents from 255 companies (399 releases) · updated Nov 7, 2026
No documents match these filters.
Monday, August 3132
- ZURAZura BioReleaseZura Bio to Participate in the Cantor Global Healthcare Conference
- VIRVir BiotechnologyReleaseVir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- SRPTSarepta TherapeuticsReleaseSarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conferencevia aggregator
- PMVPPMV PharmaceuticalsReleasePMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial→ BD updateSummary on the 8-K
- PMVPPMV PharmaceuticalsReleasePMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities→ BD updateSummary on the 8-K
- PMVPPMV PharmaceuticalsReleasePMV Pharma Announces Proposed Public Offering of Securities→ BD updateSummary on the 8-K
- PMVPPMV Pharmaceuticals8-KCurrent report: other events · EX-99.1→ BD updateToday PMVP dropped two punches simultaneously: the PYNNACLE May data cut shows ORR holding at 46% (35/76) while median duration of response vaulted to 10.0 months — and in the same breath, management finally pulled the trigger on the dilution event I've been warning about since the original deep dive, killing the ATM and launching an underwritten secondary with warrants via TD Cowen.BD extracted 1 program update from this document → PMVP pipeline
- PMVPPMV Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- PMVPPMV Pharmaceuticals424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
- NRSNNeuroSense TherapeuticsReleaseThree-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen...→ BD updateNeuroSense just scrapped the original 300-patient PARAGON design and replaced it with a three-part "capital-efficient" program — a smaller/shorter pivotal, a head-to-head vs. edaravone, and AI-enabled PK modeling — while guiding a Canada NDS for December 2026. Whether this is a smart pivot or a forced retreat from a trial the company was never going to fund is the question that matters.BD extracted 1 program update from this document → NRSN pipeline
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- KZIAKazia Therapeutics6-KForeign issuer report
- KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 LAUNCH PRESS RELEASE OF KAZIA THERAPEUTICS LIMITED DATED AUGUST 27, 2026
- KZIAKazia Therapeutics424B5Prospectus supplement (offering)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- GRCEGrace TherapeuticsEFFECTRegistration effective
- EXELExelixisReleaseExelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories→ BD updateSummary on the 8-K
- EXELExelixis8-KCurrent report: other events→ BD updateThe Federal Circuit just upheld the three cabozantinib salt patents that define the January 2030 exclusivity floor, removing the appellate-level overhang that was the biggest near-term threat to the Zanza Switch bridge strategy.
- ELTXElicio TherapeuticsReleaseElicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED AUGUST 31, 2026→ BD updateIMPACT pancreatic cancer enrollment is complete at 48 patients — 4x the original 12 — with data targeted for early 2027 and a pivotal study now in active planning. The pancreas franchise just crossed another structural milestone on today's tape.BD extracted 1 program update from this document → DRTS pipeline
- CYDYCytoDyn10-KAnnual report→ BD updateCytoDyn's FY2026 10-K confirms a fresh $16.5M private placement closing August 28, a reissued going concern opinion, a $42.7M net loss, and the class-action settlement on track for November final approval — a balance-sheet status check heading into the make-or-break ESMO October catalyst.
- CMMBChemomab TherapeuticsReleaseChemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor ConferenceBD extracted 1 program update from this document → CMMB pipelinecompany site may be offline after the acquisition
- CHRSCoherus OncologyReleaseCoherus to Participate in Upcoming Investor Conferences
- BEAMBeam TherapeuticsReleaseBeam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateAlterity pulled the first financing trigger today: an underwriting agreement to raise A$4.2–7.96M via expiring listed options — real cash, but a down-payment on a Phase 3 budget that needs multiples more, and a signal the dual-track process is live.
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateSummary on the 6-K
- ATAIAtai Beckley8-KCurrent report: other events
- ARVNArvinasS-8Employee plan registration
- APVOAptevo TherapeuticsDEF 14AProxy statement
- APVOAptevo TherapeuticsCORRESPCORRESP
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Announces Participation in September Investor Conference
- ACRVAcrivon TherapeuticsReleaseAcrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Saturday, August 291
- TENXTenax TherapeuticsReleaseTenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026→ BD updateThe full LEVEL dataset landed at ESC Munich, and the subgroup story got sharper — but the primary endpoint miss stands, and a prespecified split in a failed trial is still a hypothesis, not a win.
Friday, August 2817
- QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million→ BD updateSummary on the 8-K
- QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome→ BD updateSummary on the 8-K
- QNRXQuoin Pharmaceuticals8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 EXHIBIT 99.1→ BD updateThe two conditions I told readers to wait for — controlled efficacy data and a funded balance sheet — landed simultaneously today: QRX003 hit its IGA primary endpoint in 4/6 (66.7%) interim patients (p=0.0087), and a $30.8M upfront PIPE closes Sunday, extending runway into 2H 2029.BD extracted 1 program update from this document → QNRX pipeline
- ORKAOruka Therapeutics424B5Prospectus supplement (offering)Oruka quietly reloaded its ATM facility with a fresh $500M capacity the same week the stock shed 13% from its all-time high — and the Week 28 EVERLAST-A durability readout, the one catalyst the entire once-yearly maintenance thesis rests on, is now imminent.
- NVCTNuvectis PharmaEFFECTRegistration effective
- MAIAMAIA BiotechnologyEFFECTRegistration effective
- KZIAKazia Therapeutics6-KForeign issuer report
- KZIAKazia Therapeutics424B5Prospectus supplement (offering)
- HURATuHURA BiosciencesSCHEDULE 13D/A13D amendment
- ENTXEntera BioEFFECTRegistration effective
- ENTXEntera Bio424B3Prospectus (resale / update)
- CRNXCrinetics Pharmaceuticals8-KCurrent report: shareholder vote→ BD updateThe shareholder vote just cleared: 99.98% of votes cast approved the Vertex merger on August 28, and the deal is expected to close September 1. The pipeline-in-a-pill thesis is officially done as a public equity story.
- CHRSCoherus Oncology8-KCurrent report: other events→ BD updateSix weeks before the casdozokitug coin flip, Coherus swapped its exhausted TD Cowen ATM for a fresh $50M Leerink Partners facility — reopening the dilution tap into a 22.6% post-Innovatus rally and changing the pre-readout capital structure calculus I laid out on August 17.
- CHRSCoherus Oncology424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- CHRSCoherus Oncology424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
- AUTLAutolus TherapeuticsSCHEDULE 13D/A13D amendment
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATHEAlterity Therapeutics20-FAnnual report (foreign)
Thursday, August 2729
- VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027→ BD updateCOVE-2 enrollment is complete and topline data is now expected Q1 2027 — roughly a quarter earlier than the mid-2027 guide — while a blinded interim power analysis confirmed no additional patients are needed, a subtle but important data-quality signal. The pull-forward compresses the funding gap in the company's favor but doesn't close it.BD extracted 1 program update from this document → VRCA pipeline
- TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RNTXRein Therapeutics8-KCurrent report: listing notice
- RCKTRocket Pharmaceuticals8-KCurrent report: officer / director change
- PCVXVaxcyteReleaseVaxcyte to Participate in Upcoming Investor Conferences
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™→ BD updateSummary on the 8-K
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference→ BD updateSummary on the 8-K
- OTLKOutlook Therapeutics8-KCurrent report: officer / director change→ BD updateThree weeks into the U.S. commercial launch, OTLK just swapped its CFO — the executive who earned a $200K approval bonus in July is out effective September 1, replaced by a capital-markets specialist whose most recent gig was a medical-device IPO. At $0.64, the stock is 54% below the approval-day close and has a Nasdaq minimum-bid problem brewing.
- ORKAOruka TherapeuticsEFFECTRegistration effective
- NRSNNeuroSense Therapeutics6-KForeign issuer report
- NBPNovaBridge BiosciencesReleaseNovaBridge Biosciences to Participate in September Investor Conferences
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MESOMesoblast20-FAnnual report (foreign)
- MBRXMoleculin BiotechReleaseMoleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conferencevia aggregator
- KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED AUGUST 27, 2026
- KZIAKazia Therapeutics424B5Prospectus supplement (offering)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- IMTXImmaticsSCHEDULE 13D/A13D amendment
- FBRXForte BiosciencesSC TO-T/ASC TO-T/A
- FBRXForte BiosciencesSC 14D9/ASC 14D9/A
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesS-8 POSEmployee plan registration (post-effective)
- FBRXForte BiosciencesReleaseargenx Completes Acquisition of Forte Biosciences, Inc.via aggregatorcompany site may be offline after the acquisition
- FBRXForte BiosciencesPOS AMPost-effective amendment
- FBRXForte BiosciencesPOS AMPost-effective amendment
- FBRXForte BiosciencesPOS AMPost-effective amendment
- FBRXForte BiosciencesPOS AMPost-effective amendment
- FBRXForte BiosciencesPOS AMPost-effective amendment
- FBRXForte BiosciencesPOS AMPost-effective amendment
- FBRXForte Biosciences8-KCurrent report: acquisition / disposition, listing notice, holder rights modified
- FBRXForte Biosciences25-NSEDelisting notice
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
- ENTXEntera BioReleaseCorrection: Entera to Participate in Upcoming Fall Investor Conferences
- ENTXEntera BioReleaseEntera to Participate in Upcoming Fall Investor Conferences
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)→ BD updateThe FDA just granted Fast Track Designation to Varseta-M in relapsed/refractory mCRC — the first formal regulatory signal on a drug the thesis has been building toward since the March data readout, and a meaningful de-risking step ahead of the planned 1H 2027 registrational study.
- CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialBD extracted 1 program update from this document → CRVS pipeline
- APVOAptevo TherapeuticsUPLOADUPLOAD
- ACETAdicet BioReleaseAdicet Bio Announces FDA Clearance of IND Application for ADI-212→ BD updateADI-212's IND just cleared — one named catalyst down, the one that actually matters still pending. Here's what changed and what didn't.
Wednesday, August 2615
- XERSXeris BiopharmaReleaseXeris Announces Details for XP-8121 Program Overview Webinar
- XENEXenon PharmaceuticalsReleaseXenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026BD extracted 1 program update from this document → XENE pipeline
- TTRXTurn TherapeuticsDForm D (exempt offering)→ BD updateTTRX quietly closed a $1.65M Rule 506(b) private placement to 8 accredited investors on August 14 — the first clean equity raise in the coverage history, bypassing both the GEM death-spiral facility and the Avenue debt tranche. It begins chipping away at the $10M equity-raise gate required to unlock Avenue Tranche 2.
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Announces Launch of MPS3BStudy.comBD extracted 1 program update from this document → SPRB pipeline
- SMMTSummit Therapeutics8-KCurrent report: other events · EX-99.1
- RVMDRevolution MedicinesReleaseU.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancervia aggregatorBD extracted 1 program update from this document → RVMD pipeline
- RVMDRevolution Medicines8-KCurrent report: other events
- RCUSArcus BiosciencesReleaseArcus Biosciences to Participate in Three Upcoming Investor Conferences
- NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
- INSMInsmedReleaseInsmed to Present at September 2026 Investor Conferences
- INMBInmune BioReleaseINmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory FilingsBD extracted 1 program update from this document → INMB pipeline
- IMTXImmatics6-KForeign issuer report · EX-99.1
- IMRXImmuneeringReleaseImmuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients→ BD updateAn FDA approval just landed in second-line pancreatic cancer — and Immuneering is using it to stake the flag on first-line, where atebimetinib and MAPKeeper 301 are the only game in town with a 17.3-month median OS signal.BD extracted 1 program update from this document → IMRX pipeline
- GOSSGossamer Bio8-KCurrent report: charter / bylaws / fiscal year
- EIKNEikon TherapeuticsReleaseEikon Therapeutics to Participate in Investor Conferences in September 2026
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Participate at Upcoming Investor Conferences and Events
- APVOAptevo TherapeuticsDForm D (exempt offering)
Tuesday, August 2520
- ZYMEZymeworksReleaseU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinomavia aggregator→ BD updateSummary on the 8-KBD extracted 1 program update from this document → ZYME pipeline
- ZYMEZymeworks8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe flywheel just caught: FDA approved two Ziihera+chemo regimens in 1L HER2+ GEA on the August 25 PDUFA date, triggering the $250M Jazz milestone that transforms the balance sheet and de-risks the royalty-aggregation thesis in one wire transfer.
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072→ BD updateSummary on the 8-KBD extracted 2 program updates from this document → SYRE pipeline
- SYRESpyre Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateSPY072 hit statistical significance in RA but fell short of Spyre's internal bar for monotherapy advancement — proof-of-mechanism confirmed, the RA Phase 3 path is closed, and the thesis pivots fully to combinations and PsA/axSpA.
- SMMTSummit TherapeuticsReleaseIvonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology→ BD updateSummary on the releaseBD extracted 1 program update from this document → SMMT pipeline
- SMMTSummit TherapeuticsReleaseIvonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria→ BD updateTwo catalysts landed today: HARMONi goes peer-reviewed in The Lancet Oncology with the WCLC updated OS presentation now confirmed for September 15, and Akeso's HARMONi-GI1 becomes the first ivonescimab Phase III win outside NSCLC — OS superiority over an active PD-L1 in biliary tract cancer. Five-for-five on Phase III readouts, 81 days before the PDUFA that counts.
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026The AURORA Phase 3 is moving from cleared IND to boots-on-the-ground enrollment: all sites locked, CRO retained, screening starting October, first patient Q4 2026 — exactly on the timeline I said to watch.
- SEPNSepterna8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- OCGNOcugenReleaseOcugen to Participate in Upcoming September Investor and Industry Conferences
- NKTRNektar TherapeuticsReleaseNektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisBD extracted 1 program update from this document → NKTR pipeline
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MBRXMoleculin BiotechSCHEDULE 13DActivist / >5% holder (13D)
- MBRXMoleculin BiotechSCHEDULE 13DActivist / >5% holder (13D)
- IXHLIncannex HealthcareReleaseIncannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X→ BD updateSummary on the 8-K
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF AUGUST 25, 2026→ BD updateThe first patient has been dosed in DReAMzz — the exact checkpoint I flagged as the next editorial moment. The milestone is real; the 2H 2027 Phase 3 wall, the $6.50 warrant overhang, and the capital-structure mess are still standing.
- IMTXImmaticsReleaseImmatics Announces $150 Million Underwritten Offering→ BD updateSummary on the 424B2
- IMTXImmatics424B2Prospectus supplement→ BD updateImmatics just closed a $150M underwritten offering at $8.69/share — below the August 18 close — adding ~17.3M shares to the float and extending cash runway deeper into 2028, but at a dilution cost worth understanding ahead of the 1H 2027 SUPRAME readout.
- GANXGain TherapeuticsReleaseGain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
- FDMT4D Molecular TherapeuticsRelease4DMT to Participate in Upcoming Investor Conferences
- BCAXBicara Therapeutics8-KCurrent report: material agreement
Monday, August 2428
- VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED AUGUST 24, 2026
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026→ BD updateThe factory finally signed off: Spruce confirmed the first PPQ batch manufactured, FDA blessed the CMC comparability strategy post-technology transfer, and the Q4 2026 BLA submission is locked — the single highest-value unknown in this name just became a fact.
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan→ BD updateJapan's MHLW has approved IMCIVREE for acquired hypothalamic obesity, the #1 catalyst on the watch list from the August 4 update — unlocking an estimated 5,000–8,000 Japanese patients and completing the U.S./EU/Japan regulatory trifecta for the HO franchise.
- ORKAOruka TherapeuticsReleaseOruka Therapeutics Appoints Todd Edwards as Chief Commercial OfficerSummary on the 8-K
- ORKAOruka Therapeutics8-KCurrent report: officer / director changeOruka just hired its first Chief Commercial Officer — a 25-year I&I/derm veteran who scaled UCB's immunology franchise and launched biologics at Incyte — directly answering the commercial execution risk I named as the core bear case.
- OCSOculis HoldingReleaseFirst Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic NeuritisThe first patient is now being treated in PIONEER-1, officially starting the 2027 data clock on the neuroprotectant carrying Oculis's entire equity — execution risk is retiring, data risk is all that remains.
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MBRXMoleculin BiotechDEFA14AProxy soliciting material
- MBRXMoleculin BiotechDEF 14AProxy statement
- LGVNLongeveronReleaseLongeveron Announces 1-for-10 Reverse Stock Split→ BD updateSummary on the 8-K
- LGVNLongeveron8-KCurrent report: charter / bylaws / fiscal year, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AUGUST 24, 2026→ BD updateThe reverse split I flagged as a defensive pre-data warning sign just executed — 1-for-10 effective August 26 — arriving days before the September ELPIS II readout and the September 21 Nasdaq delisting deadline, confirming the structural squeeze thesis.
- INSMInsmedReleaseBRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease→ BD updateBRINSUPRI just cleared its final major regulatory hurdle — Japan MHLW approval today — completing the US/EU/UK/Japan sweep and adding ~150,000 diagnosed patients to the addressable market, even as the stock sits 6% off recent highs and management's own guidance excludes near-term Japan revenue contribution.
- GUTSFractyl HealthDEF 14AProxy statement
- GRCEGrace TherapeuticsS-3Shelf registration
- GOSSGossamer BioSCHEDULE 13D/A13D amendment
- GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant P
- ERASErascaReleaseErasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma→ BD updateSummary on the 8-K
- ERASErasca8-KCurrent report: other events→ BD updateThe FDA has granted Fast Track Designation to ERAS-0015 in metastatic pancreatic adenocarcinoma — the first clean regulatory win since the April 28 Grade 5 pneumonitis crash, and a direct accelerant to the PDAC Phase 3 path that Charles Fuchs was just hired to run.
- ELTXElicio TherapeuticsReleaseElicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
- DTILPrecision BiosciencesSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- DTILPrecision BiosciencesReleasePrecision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study→ BD updateSummary on the 8-K
- DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe first patient has been dosed in FUNCTION-DMD — the "not yet dosed" bear-case bullet from the deep dive officially closed today, but the real test (AAV safety in a class under a Boxed Warning) is just beginning.
- CAPRCapricor TherapeuticsReleaseCapricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA→ BD updateSummary on the 8-KBD extracted 1 program update from this document → CAPR pipeline
- CAPRCapricor Therapeutics8-KCurrent report: other events · EX-99.1→ BD updateThe FDA has formally accepted Capricor's BLA amendment as a major amendment and set November 22 as the new PDUFA date — the August 22 binary is officially closed, the skeletal-only refined indication strategy is now the company's official regulatory path, and the clock running at $40M/quarter just got three months longer.
- BMEABiomea FusionReleaseBiomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes→ BD updateCOVALENT-211 just closed enrollment at 64 patients — the "near completion" watch-list item from the August 5 update is now confirmed, locking in the Q1 2027 readout for the make-or-break T2D trial and setting a year-end target for COVALENT-212.
- BLTEBelite BioReleaseBelite Bio to Host Virtual Commercial Day on September 2, 2026
- BCTXBriaCell TherapeuticsReleaseBriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™via aggregator
- ANIXAnixa BiosciencesReleaseAnixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Saturday, August 221
- VNDAVanda PharmaceuticalsReleaseNEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Friday, August 2120
- SABSSAB Biotherapeutics424B3Prospectus (resale / update)
- ORKAOruka TherapeuticsS-3Shelf registration
- NVCTNuvectis PharmaS-3Shelf registration→ BD update
- NVCTNuvectis Pharma8-KCurrent report: other events→ BD update
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
- MBRXMoleculin Biotech424B5Prospectus supplement (offering)
- MAIAMAIA BiotechnologyS-3Shelf registration
- KTTAPasithea Therapeutics8-KCurrent report: listing notice
- KAPAKairos PharmaReleaseKairos Pharma Announces 1-for-7 Reverse Stock Split
- KAPAKairos Pharma8-KCurrent report: holder rights modified, charter / bylaws / fiscal year, Reg FD disclosure · EX-99.1
- HURATuHURA Biosciences8-KCurrent report: debt / obligation
- GOSSGossamer BioReleaseGossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval→ BD updateSummary on the 8-K
- GOSSGossamer Bio8-KCurrent report: material agreement, unregistered sale of equity, charter / bylaws / fiscal year · EX-99.1→ BD updateGossamer closes a $25M initial tranche today and commits investors to $125M more upon FDA NDA acceptance — a structured lifeline that pushes runway into 2028 and defuses the March 2027 springing maturity trigger, at the cost of another massive equity dilution wave.
- FBRXForte BiosciencesSC 14D9/ASC 14D9/A
- ENTXEntera BioS-3Shelf registration
- CUECue BiopharmaSCHEDULE 13DActivist / >5% holder (13D)→ BD updateThe July PIPE resale S-3 went effective August 20, freeing ~1.5M institutional shares into a 7.4M-share float — and the stock cratered 30% to $23.98. The CEO's 13D simultaneously reveals that the company sold 58,258 shares on her behalf for tax withholding, not a discretionary exit, and that her $33 PSU tranche already vested.
- CAPRCapricor TherapeuticsReleaseKaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholdersvia aggregator→ BD update
- BLTEBelite BioReleaseBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesBD extracted 1 program update from this document → BLTE pipeline
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- APVOAptevo TherapeuticsS-1Registration statement
- APVOAptevo TherapeuticsPRE 14APRE 14A
- APVOAptevo Therapeutics8-KCurrent report: shareholder vote
Thursday, August 2014
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and ItchBD extracted 1 program update from this document → TTRX pipeline
- TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
- QNRXQuoin Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote, other events
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
- NBPNovaBridge BiosciencesReleaseNovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic ExecutionBD extracted 3 program updates from this document → NBP pipeline
- NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
- NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
- MPLTMapLight TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- GUTSFractyl HealthReleaseFractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight MaintenanceBD extracted 1 program update from this document → GUTS pipeline
- CUECue BiopharmaEFFECTRegistration effective
- BCYCBicycle Therapeutics8-KCurrent report: officer / director change
- AMLXAmylyx Pharmaceuticals8-KCurrent report: material agreement
- AMLXAmylyx Pharmaceuticals424B5Prospectus supplement (offering)
- ALLOAllogene TherapeuticsEFFECTRegistration effective
- ADAGAdageneReleaseAdagene to Participate in Three Upcoming Investor Conferences
- ACIUAC ImmuneReleaseAC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764BD extracted 1 program update from this document → ACIU pipeline
- ACIUAC Immune6-KForeign issuer report · EX-99.1
Wednesday, August 1913
- ZNTLZentalis PharmaceuticalsSCHEDULE 13G/A13G amendment
- ZBIOZenas BioPharmaSCHEDULE 13D/A13D amendment
- VNDAVanda PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- RAREUltragenyx PharmaceuticalReleaseUltragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)BD extracted 1 program update from this document → RARE pipeline
- RAREUltragenyx Pharmaceutical8-KCurrent report: other events
- OTLKOutlook TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- LGVNLongeveronReleaseLongeveron Appoints Nirav Jhaveri as Chief Financial Officer
- LGVNLongeveron8-KCurrent report: officer / director change · EX-99.1 PRESS RELEASE
- KZIAKazia TherapeuticsSCHEDULE 13G/A13G amendment
- KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
- KPRXKiora Pharmaceuticals8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- HURATuHURA Biosciences8-KCurrent report: unregistered sale of equity, shareholder vote
- HELPHelus PharmaDForm D (exempt offering)
- HELPHelus PharmaDForm D (exempt offering)
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- FBRXForte BiosciencesSC TO-T/ASC TO-T/A
- FBRXForte BiosciencesSC 14D9/ASC 14D9/A
- CRNXCrinetics Pharmaceuticals8-KCurrent report: other events
- CMMBChemomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CGEMCullinan TherapeuticsReleaseZipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung CancerBD extracted 1 program update from this document → CGEM pipeline
- CAPRCapricor TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Tuesday, August 1828
- TTRXTurn Therapeutics8-KCurrent report: unregistered sale of equity
- TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- PCSAProcessa PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- OTLKOutlook Therapeutics10-QQuarterly report
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- MPLTMapLight TherapeuticsSCHEDULE 13D/A13D amendment
- MESOMesoblast6-KForeign issuer report · EX-99.1
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- IMTXImmaticsReleaseImmatics Announces Second Quarter 2026 Financial Results and Business Update
- IMTXImmatics6-KForeign issuer report · EX-99.1
- IBRXImmunityBioReleaseWorld Lung IASLC (WCLC)
- IBRXImmunityBioReleaseMaTOS
- IBRXImmunityBioReleaseSITC
- IBRXImmunityBioReleaseESMO
- IBRXImmunityBioReleaseESMO Asia
- IBRXImmunityBioReleaseASH Annual Meeting
- IBRXImmunityBioReleaseAHNS 2026 International Conference on Head and Neck Cancer
- IBRXImmunityBioReleaseThoracic Rare Cancer Symposium (THORACS)
- IBRXImmunityBioReleaseSNO (Society of Neuro Oncology)
- HELPHelus PharmaReleaseHelus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- ENTXEntera BioReleaseEntera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
- ENTXEntera Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- EIKNEikon TherapeuticsReleaseEikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
- CUECue BiopharmaCORRESPCORRESP
- ANIXAnixa BiosciencesReleaseAnixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBD extracted 1 program update from this document → ANIX pipeline
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
- AMLXAmylyx Pharmaceuticals8-KCurrent report: other events · EX-99.1BD extracted 2 program updates from this document → AMLX pipeline
- AMLXAmylyx Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- AMLXAmylyx Pharmaceuticals424B5Prospectus supplement (offering)
Monday, August 1717
- ZURAZura Bio8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- ZBIOZenas BioPharmaSCHEDULE 13D/A13D amendment
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
- OTLKOutlook TherapeuticsNT 10-QNT 10-Q
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
- NRXPNRX Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- NBPNovaBridge BiosciencesS-8Employee plan registration
- MAZEMaze Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- EYPTEyePointReleaseEyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMDBD extracted 1 program update from this document → EYPT pipeline
- EYPTEyePoint8-KCurrent report: other events · EX-99.1
- CUECue BiopharmaUPLOADUPLOAD
- CLNNCleneReleaseClene to Present at the Emerging Growth Conference
- CHRSCoherus OncologyReleaseCoherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
- CHRSCoherus Oncology8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- CHRSCoherus Oncology8-KCurrent report: material agreement, agreement terminated, debt / obligation
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARDXArdelyx8-KCurrent report: other events
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026BD extracted 1 program update from this document → AMLX pipeline
- ACHVAchieve Life SciencesSCHEDULE 13GPassive >5% holder (13G)
- AARDAardvark Therapeutics8-KCurrent report: shareholder vote
Friday, August 1455
- ZNTLZentalis Pharmaceuticals8-KCurrent report: other events
- ZNTLZentalis Pharmaceuticals424B5Prospectus supplement (offering)
- XFORX4 PharmaceuticalsSCHEDULE 13G/A13G amendment
- XFORX4 PharmaceuticalsSCHEDULE 13G/A13G amendment
- WVEWave Life SciencesEFFECTRegistration effective
- VYGRVoyager TherapeuticsSCHEDULE 13G/A13G amendment
- VSTMVerastemSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VERAVera TherapeuticsSCHEDULE 13G/A13G amendment
- UNCYUnicycive TherapeuticsSCHEDULE 13G/A13G amendment
- UNCYUnicycive TherapeuticsSCHEDULE 13G/A13G amendment
- TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
- TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
- TVTXTravere TherapeuticsSCHEDULE 13G/A13G amendment
- TSHATaysha Gene TherapiesSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- SYRESpyre TherapeuticsSCHEDULE 13G/A13G amendment
- SYRESpyre TherapeuticsSCHEDULE 13G/A13G amendment
- STROSutro BiopharmaSCHEDULE 13G/A13G amendment
- STROSutro BiopharmaSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- SRPTSarepta Therapeutics13F-HR13F-HR
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- SPRBSpruce BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- SLDBSolid BiosciencesSCHEDULE 13G/A13G amendment
- SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
- SGMTSagimet BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- SEPNSepternaSCHEDULE 13G/A13G amendment
- SEPNSepternaSCHEDULE 13D/A13D amendment
- SCYXScynexisSCHEDULE 13G/A13G amendment
- SCYXScynexisSCHEDULE 13G/A13G amendment
- SANASana BiotechnologySCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- RVMDRevolution MedicinesSCHEDULE 13GPassive >5% holder (13G)
- RNTXRein TherapeuticsSCHEDULE 13G/A13G amendment
- RNTXRein TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RNTXRein Therapeutics10-QQuarterly report
- RLMDRelmada TherapeuticsSCHEDULE 13G/A13G amendment
- RLAYRelay TherapeuticsSCHEDULE 13G/A13G amendment
- REPLReplimune GroupSCHEDULE 13G/A13G amendment
- REPLReplimune GroupS-3ASRAutomatic shelf registration
- REPLReplimune GroupReleaseReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
- REPLReplimune Group8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- REPLReplimune Group10-QQuarterly report
- RAREUltragenyx PharmaceuticalSCHEDULE 13GPassive >5% holder (13G)
- RAPPRapport TherapeuticsSCHEDULE 13G/A13G amendment
- RAPPRapport TherapeuticsSCHEDULE 13G/A13G amendment
- QUREuniQureSCHEDULE 13G/A13G amendment
- QUREuniQureSCHEDULE 13GPassive >5% holder (13G)
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- QNRXQuoin Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- QNRXQuoin Pharmaceuticals10-QQuarterly report
- PTNPalatin TechnologiesSCHEDULE 13G/A13G amendment
- PMVPPMV PharmaceuticalsReleasePMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate HighlightsBD extracted 1 program update from this document → PMVP pipeline
- PMVPPMV Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- PMVPPMV Pharmaceuticals10-QQuarterly report
- PMNProMIS NeurosciencesSCHEDULE 13G/A13G amendment
- PHIOPhio PharmaceuticalsDEFA14AProxy soliciting material
- PHIOPhio PharmaceuticalsDEF 14AProxy statement
- PHIOPhio PharmaceuticalsARSAnnual report to shareholders
- PCSAProcessa Pharmaceuticals10-QQuarterly reportBD extracted 1 program update from this document → PCSA pipeline
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OTLKOutlook TherapeuticsSCHEDULE 13D/A13D amendment
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
- OTLKOutlook Therapeutics8-KCurrent report: other events
- OTLKOutlook Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
- ORKAOruka TherapeuticsSCHEDULE 13G/A13G amendment
- ORKAOruka TherapeuticsSCHEDULE 13G/A13G amendment
- ORKAOruka TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- OKUROnKure TherapeuticsSCHEDULE 13G/A13G amendment
- OKUROnKure TherapeuticsSCHEDULE 13G/A13G amendment
- OKUROnKure TherapeuticsSCHEDULE 13G/A13G amendment
- OCSOculis HoldingReleaseOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilitiesvia aggregator
- OCGNOcugenDEFA14AProxy soliciting material
- NRXPNRX Pharmaceuticals10-QQuarterly report
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NRIXNurix TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NKTRNektar TherapeuticsSCHEDULE 13G/A13G amendment
- NKTRNektar TherapeuticsSCHEDULE 13G/A13G amendment
- NKTRNektar TherapeuticsS-8Employee plan registration
- NKTRNektar Therapeutics10-QQuarterly report
- NGNENeurogeneSCHEDULE 13G/A13G amendment
- NGNENeurogeneSCHEDULE 13G/A13G amendment
- NGNENeurogeneSCHEDULE 13GPassive >5% holder (13G)
- NAMSNewAmsterdam Pharma8-K/ACurrent report (amended): officer / director change
- NAMSNewAmsterdam Pharma8-KCurrent report: officer / director change
- MRKRMarker Therapeutics10-QQuarterly report
- MLTXMoonLake ImmunotherapeuticsSCHEDULE 13G/A13G amendment
- MLTXMoonLake ImmunotherapeuticsSCHEDULE 13G/A13G amendment
- MLTXMoonLake ImmunotherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- MGTXMeiraGTxSCHEDULE 13G/A13G amendment
- MDNAFMedicenna TherapeuticsReleaseMedicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming ConferencesBD extracted 1 program update from this document → MDNAF pipeline
- MBRXMoleculin BiotechPRE 14APRE 14A
- MBRXMoleculin Biotech8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- MAZEMaze TherapeuticsSCHEDULE 13G/A13G amendment
- MAIAMAIA BiotechnologySCHEDULE 13G/A13G amendment
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment
- LXEOLexeo TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- LQDALiquidiaSCHEDULE 13G/A13G amendment
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- KZIAKazia TherapeuticsSCHEDULE 13G/A13G amendment
- KZIAKazia TherapeuticsSCHEDULE 13G/A13G amendment
- KYTXKyverna TherapeuticsSCHEDULE 13G/A13G amendment
- KYMRKymera TherapeuticsSCHEDULE 13G/A13G amendment
- KURAKura OncologySCHEDULE 13G/A13G amendment
- KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
- KTTAPasithea Therapeutics10-QQuarterly report
- KPRXKiora PharmaceuticalsSCHEDULE 13G/A13G amendment
- KPRXKiora PharmaceuticalsSCHEDULE 13G/A13G amendment
- KODKodiak SciencesSCHEDULE 13GPassive >5% holder (13G)
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- JANXJanux TherapeuticsSCHEDULE 13G/A13G amendment
- IXHLIncannex HealthcareSCHEDULE 13GPassive >5% holder (13G)
- IVVDInvivydSCHEDULE 13G/A13G amendment
- IVVDInvivydSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsEFFECTRegistration effective
- INSMInsmedSCHEDULE 13G/A13G amendment
- INBXInhibrx BiosciencesSCHEDULE 13G/A13G amendment
- INBXInhibrx BiosciencesSCHEDULE 13G/A13G amendment
- INBXInhibrx BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- IMVTImmunovantSCHEDULE 13G/A13G amendment
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMUXImmunicSCHEDULE 13GPassive >5% holder (13G)
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- IMNMImmunomeSCHEDULE 13G/A13G amendment
- IMNMImmunomeSCHEDULE 13G/A13G amendment
- IMMXImmix BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- IMCRImmunocoreSCHEDULE 13G/A13G amendment
- IDYAIDEAYA BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- HURATuHURA Biosciences8-KCurrent report: results of operations · EX-99.1
- HURATuHURA Biosciences10-QQuarterly report
- HELPHelus PharmaSCHEDULE 13G/A13G amendment
- HELPHelus PharmaReleaseHelus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → HELP pipeline
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- GUTSFractyl HealthPRE 14APRE 14A
- GRCEGrace TherapeuticsSCHEDULE 13G/A13G amendment
- GRCEGrace TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- GERNGeronSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- EYPTEyePointSCHEDULE 13G/A13G amendment
- EXELExelixisSCHEDULE 13D/A13D amendment
- EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment
- EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment
- EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment
- EVMNEvommuneSCHEDULE 13G/A13G amendment
- EVMNEvommuneSCHEDULE 13GPassive >5% holder (13G)
- ERASErascaSCHEDULE 13G/A13G amendment
- ENTAEnanta PharmaceuticalsSCHEDULE 13G/A13G amendment
- ENTAEnanta PharmaceuticalsSCHEDULE 13G/A13G amendment
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- EIKNEikon Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
- DFTXDefinium TherapeuticsSCHEDULE 13G/A13G amendment
- DFTXDefinium TherapeuticsSCHEDULE 13G/A13G amendment
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- CUECue BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- CUECue BiopharmaReleaseCue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- CUECue Biopharma8-KCurrent report: results of operations · EX-99.1
- CUECue Biopharma10-QQuarterly report
- CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CRVOCervoMedSCHEDULE 13G/A13G amendment
- CRVOCervoMedSCHEDULE 13G/A13G amendment
- CRVOCervoMedSCHEDULE 13GPassive >5% holder (13G)
- CRVOCervoMedSCHEDULE 13GPassive >5% holder (13G)
- CRNXCrinetics Pharmaceuticals8-KCurrent report: other events
- CRDLCardiol TherapeuticsSCHEDULE 13G/A13G amendment
- CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment
- CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment
- CMPXCompass TherapeuticsSCHEDULE 13G/A13G amendment
- CLYMClimb BioSCHEDULE 13G/A13G amendment
- CLYMClimb Bio8-KCurrent report: other events
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLNNCleneSCHEDULE 13G/A13G amendment
- CLNNCleneReleaseClene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
- CLNNClene8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CLNN pipeline
- CLNNClene10-QQuarterly report
- CLDXCelldex TherapeuticsSCHEDULE 13G/A13G amendment
- CLDXCelldex TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CGONCG OncologySCHEDULE 13G/A13G amendment
- CGONCG OncologySCHEDULE 13G/A13G amendment
- CGEMCullinan TherapeuticsSCHEDULE 13G/A13G amendment
- CGEMCullinan TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CBIOCrescent BiopharmaSCHEDULE 13G/A13G amendment
- CAPRCapricor TherapeuticsSCHEDULE 13G/A13G amendment
- CAPRCapricor Therapeutics10-QQuarterly report
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- BIOABioAge LabsSCHEDULE 13G/A13G amendment
- BEAMBeam TherapeuticsSCHEDULE 13G/A13G amendment
- BCYCBicycle TherapeuticsSCHEDULE 13G/A13G amendment
- BCRXBiocryst PharmaceuticalsSCHEDULE 13G/A13G amendment
- AUTLAutolus TherapeuticsSCHEDULE 13G/A13G amendment
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARVNArvinasSCHEDULE 13G/A13G amendment
- ARTVArtiva BiotherapeuticsSCHEDULE 13G/A13G amendment
- ARTVArtiva BiotherapeuticsEFFECTRegistration effective
- ARDXArdelyxSCHEDULE 13GPassive >5% holder (13G)
- APVOAptevo TherapeuticsSCHEDULE 13G/A13G amendment
- APVOAptevo TherapeuticsReleaseAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsBD extracted 1 program update from this document → APVO pipeline
- APVOAptevo Therapeutics8-KCurrent report: results of operations · EX-99.1
- APVOAptevo Therapeutics10-QQuarterly report
- ANABAnaptysBioSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
- ADCTADC TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ADAGAdageneSCHEDULE 13G/A13G amendment
- ACTUActuate Therapeutics10-QQuarterly report
- ACRSAclaris TherapeuticsSCHEDULE 13G/A13G amendment
- ACHVAchieve Life Sciences8-KCurrent report: other events
- ACHVAchieve Life Sciences424B5Prospectus supplement (offering)
- ACETAdicet BioSCHEDULE 13G/A13G amendment
- ABVXAbivaxSCHEDULE 13G/A13G amendment
Thursday, August 1398
- ZNTLZentalis PharmaceuticalsSCHEDULE 13G/A13G amendment
- ZNTLZentalis Pharmaceuticals424B5Prospectus supplement (offering)
- ZBIOZenas BioPharmaReleaseZenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 1 program update from this document → ZBIO pipeline
- ZBIOZenas BioPharma8-KCurrent report: results of operations, officer / director change · EX-99.1 EXHIBIT 99.1
- ZBIOZenas BioPharma10-QQuarterly report
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VNDAVanda PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- TSHATaysha Gene TherapiesSCHEDULE 13G/A13G amendment
- TARAProtara TherapeuticsSCHEDULE 13G/A13G amendment
- SRPTSarepta TherapeuticsSCHEDULE 13G/A13G amendment
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
- SGMTSagimet Biosciences8-KCurrent report: other events
- RVPHReviva PharmaceuticalsSCHEDULE 13G/A13G amendment
- RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
- RVMDRevolution MedicinesSCHEDULE 13GPassive >5% holder (13G)
- RNTXRein TherapeuticsSCHEDULE 13G/A13G amendment
- RNACCartesian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RAREUltragenyx PharmaceuticalSCHEDULE 13GPassive >5% holder (13G)
- PYPDPolyPidSCHEDULE 13G/A13G amendment
- PTGXProtagonist TherapeuticsSCHEDULE 13G/A13G amendment
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- PMNProMIS NeurosciencesSCHEDULE 13G/A13G amendment
- PMNProMIS NeurosciencesSCHEDULE 13G/A13G amendment
- PMNProMIS NeurosciencesReleaseProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
- PMNProMIS Neurosciences8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → PMN pipeline
- PMNProMIS Neurosciences10-QQuarterly report
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsReleaseOvid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
- OVIDOvid Therapeutics8-KCurrent report · EX-99.1BD extracted 1 program update from this document → OVID pipeline
- OVIDOvid Therapeutics10-QQuarterly report
- OMEROmerosS-8Employee plan registration
- OMEROmeros8-KCurrent report: officer / director change
- OLMAOlema Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- OKUROnKure Therapeutics8-KCurrent report: officer / director change
- OCGNOcugenSCHEDULE 13G/A13G amendment
- NRSNNeuroSense TherapeuticsReleaseNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today...
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 CEO LETTER
- NKTRNektar TherapeuticsReleaseNektar Therapeutics Announces Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → NKTR pipeline
- NKTRNektar Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS."
- NGENNervGen PharmaReleaseNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBD extracted 1 program update from this document → NGEN pipeline
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- NBPNovaBridge BiosciencesReleaseNovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
- MPLTMapLight TherapeuticsReleaseMapLight Therapeutics Announces $150 Million Private Placement Financing
- MPLTMapLight TherapeuticsReleaseMapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- MPLTMapLight Therapeutics8-KCurrent report: material agreement, results of operations, unregistered sale of equity · EX-99.1BD extracted 2 program updates from this document → MPLT pipeline
- MPLTMapLight Therapeutics10-QQuarterly report
- MGTXMeiraGTxS-8Employee plan registration
- MGTXMeiraGTx8-KCurrent report: results of operations · EX-99.1
- MGTXMeiraGTx10-QQuarterly report
- MBRXMoleculin Biotech10-QQuarterly report
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment
- LGVNLongeveronSCHEDULE 13G/A13G amendment
- KYMRKymera TherapeuticsSCHEDULE 13G/A13G amendment
- KODKodiak SciencesReleaseKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → KOD pipeline
- KODKodiak Sciences8-KCurrent report: results of operations · EX-99.1
- KODKodiak Sciences10-QQuarterly report
- JANXJanux TherapeuticsSCHEDULE 13G/A13G amendment
- IVVDInvivyd8-KCurrent report: results of operations · EX-99.1
- IVVDInvivyd10-QQuarterly report
- IRDOpus GeneticsCORRESPCORRESP
- INKTMiNK TherapeuticsS-8Employee plan registration
- INKTMiNK TherapeuticsReleaseMiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung InjuryBD extracted 1 program update from this document → INKT pipeline
- INKTMiNK Therapeutics8-KCurrent report: results of operations · EX-99.1
- INKTMiNK Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → INKT pipeline
- INBXInhibrx Biosciences8-KCurrent report: results of operations · EX-99.1
- INBXInhibrx Biosciences10-QQuarterly report
- INABIN8bioSCHEDULE 13G/A13G amendment
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMMXImmix BiopharmaSCHEDULE 13G/A13G amendment
- IMCRImmunocoreSCHEDULE 13G/A13G amendment
- HURATuHURA Biosciences8-KCurrent report: debt / obligation
- GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
- GRCEGrace Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- GRCEGrace Therapeutics10-QQuarterly report
- GOSSGossamer BioReleaseGossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
- GOSSGossamer Bio8-KCurrent report: results of operations · EX-99.1
- GOSSGossamer Bio10-QQuarterly report
- GNLXGeneluxReleaseGenelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- GNLXGenelux10-QQuarterly report
- FDMT4D Molecular TherapeuticsRelease4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesBD extracted 1 program update from this document → FDMT pipeline
- FDMT4D Molecular Therapeutics8-KCurrent report: results of operations · EX-99.1
- FDMT4D Molecular Therapeutics10-QQuarterly report
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBIOFortress BiotechReleaseFortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsBD extracted 3 program updates from this document → FBIO pipeline
- FBIOFortress Biotech8-KCurrent report: results of operations · EX-99.1
- FBIOFortress Biotech10-QQuarterly report
- FATEFate TherapeuticsS-8Employee plan registration
- FATEFate Therapeutics8-KCurrent report: results of operations · EX-99.1
- FATEFate Therapeutics10-QQuarterly report
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → ETON pipeline
- ETONEton Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → ETON pipeline
- ETONEton Pharmaceuticals10-QQuarterly report
- ELTXElicio TherapeuticsReleaseElicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- ELTXElicio Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → ELTX pipeline
- ELTXElicio Therapeutics10-QQuarterly report
- ELDNEledon PharmaceuticalsReleaseEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlightsvia aggregator
- ELDNEledon Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ELDNEledon Pharmaceuticals10-QQuarterly report
- EIKNEikon TherapeuticsReleaseEikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
- EIKNEikon Therapeutics8-KCurrent report: results of operations · EX-99.1
- EIKNEikon Therapeutics10-QQuarterly report
- DYNDyne TherapeuticsSCHEDULE 13G/A13G amendment
- DYNDyne TherapeuticsSCHEDULE 13G/A13G amendment
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
- CRBUCaribou Biosciences8-KCurrent report: results of operations · EX-99.1BD extracted 2 program updates from this document → CRBU pipeline
- CRBUCaribou Biosciences10-QQuarterly report
- COGTCogent BiosciencesSCHEDULE 13G/A13G amendment
- CMMBChemomab TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLRBCellectar BiosciencesReleaseCellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates LEARN MOREBD extracted 1 program update from this document → CLRB pipeline
- CLRBCellectar Biosciences8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- CLRBCellectar Biosciences10-QQuarterly report
- CINGCingulateReleaseCingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readinessvia aggregatorBD extracted 1 program update from this document → CING pipeline
- CINGCingulate8-KCurrent report: results of operations · EX-99.1
- CINGCingulate10-QQuarterly report
- CGONCG OncologySCHEDULE 13G/A13G amendment
- CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- CATXPerspective TherapeuticsSCHEDULE 13G/A13G amendment
- CAPRCapricor TherapeuticsReleaseCapricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 1 program update from this document → CAPR pipeline
- CAPRCapricor Therapeutics8-KCurrent report: results of operations · EX-99.1
- CADLCandel Therapeutics8-KCurrent report: results of operations · EX-99.1
- CADLCandel Therapeutics10-QQuarterly report
- CABACabaletta BioReleaseCabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateBD extracted 2 program updates from this document → CABA pipeline
- CABACabaletta Bio8-KCurrent report: results of operations · EX-99.1
- CABACabaletta Bio10-QQuarterly report
- BMEABiomea FusionReleaseBiomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
- BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- BEAMBeam TherapeuticsSCHEDULE 13G/A13G amendment
- BCAXBicara TherapeuticsSCHEDULE 13G/A13G amendment
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- APVOAptevo TherapeuticsReleaseAptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
- APVOAptevo Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
- AKTSAktis OncologyReleaseAKTIS ONCOLOGY REPORTS FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE SECOND QUARTER 2026BD extracted 1 program update from this document → AKTS pipeline
- AKTSAktis Oncology8-KCurrent report: results of operations · EX-99.1
- AKTSAktis Oncology10-QQuarterly reportBD extracted 1 program update from this document → AKTS pipeline
- ADCTADC TherapeuticsS-8Employee plan registration
- ADCTADC TherapeuticsReleaseADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdatesBD extracted 1 program update from this document → ADCT pipeline
- ADCTADC Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- ADCTADC Therapeutics10-QQuarterly report
- ACRVAcrivon TherapeuticsSCHEDULE 13G/A13G amendment
- ACHVAchieve Life SciencesSCHEDULE 13GPassive >5% holder (13G)
- ABVXAbivaxSCHEDULE 13G/A13G amendment
Wednesday, August 1280
- UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
- UNCYUnicycive Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED AUGUST 12, 2026
- UNCYUnicycive Therapeutics10-QQuarterly report
- TVTXTravere TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
- TTRXTurn Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED AUGUST 12, 2026BD extracted 1 program update from this document → TTRX pipeline
- TTRXTurn Therapeutics10-QQuarterly report
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- STROSutro BiopharmaReleaseSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Studyvia aggregatorBD extracted 1 program update from this document → STRO pipeline
- STROSutro Biopharma8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- STROSutro Biopharma10-QQuarterly report
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesReleaseCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- SPRBSpruce Biosciences8-KCurrent report: results of operations · EX-99.1
- SPRBSpruce Biosciences10-QQuarterly report
- SMMTSummit TherapeuticsReleaseIvonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung CancerBD extracted 2 program updates from this document → SMMT pipeline
- SCYXScynexisSCHEDULE 13GPassive >5% holder (13G)
- SABSSAB BiotherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RVPHReviva PharmaceuticalsReleaseReviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- RVPHReviva Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- RVPHReviva Pharmaceuticals10-QQuarterly report
- RAPPRapport TherapeuticsSCHEDULE 13G/A13G amendment
- PYPDPolyPidSCHEDULE 13G/A13G amendment
- PYPDPolyPidS-8Employee plan registration
- PYPDPolyPidReleasePolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → PYPD pipeline
- PYPDPolyPid6-KForeign issuer report · EX-99.1 POLYPID LTD.'S INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2026
- PYPDPolyPid6-KForeign issuer report · EX-99.1 PRESS RELEASE ISSUED BY POLYPID LTD. ON AUGUST 12, 2026, TITLED "POLYPID PROVIDE
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
- OTLKOutlook Therapeutics8-KCurrent report: results of operations, other events · EX-99.1 EXHIBIT 99.1
- OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
- ORKAOruka TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ONCYOncolytics Biotech10-QQuarterly report
- OMEROmerosReleaseOmeros Corporation Reports Second Quarter 2026 Financial Results
- OMEROmeros8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- OMEROmeros10-QQuarterly reportBD extracted 1 program update from this document → OMER pipeline
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- MISTMilestone Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- MISTMilestone Pharmaceuticals10-QQuarterly reportBD extracted 1 program update from this document → MIST pipeline
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsBD extracted 2 program updates from this document → LXEO pipelinecompany site may be offline after the acquisition; linked to the SEC copy · original
- LXEOLexeo Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- LXEOLexeo Therapeutics10-QQuarterly report
- LQDALiquidia8-KCurrent report: results of operations, other events · EX-99.1 EXHIBIT 99.1
- LQDALiquidia10-QQuarterly report
- LGVNLongeveronReleaseLongeveron Announces 2026 Second Quarter Financial Results and Provides Business UpdateBD extracted 1 program update from this document → LGVN pipeline
- LGVNLongeveron8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON AUGUST 12, 2026
- LGVNLongeveron10-QQuarterly report
- KURAKura OncologyReleaseKura Oncology Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → KURA pipeline
- KURAKura Oncology8-KCurrent report: results of operations · EX-99.1
- KURAKura Oncology10-QQuarterly reportBD extracted 1 program update from this document → KURA pipeline
- KAPAKairos Pharma10-QQuarterly report
- IRDOpus GeneticsUPLOADUPLOAD
- IPSCCentury TherapeuticsReleaseCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- IPSCCentury Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- IPSCCentury Therapeutics10-QQuarterly report
- IMUXImmunicS-8Employee plan registration
- HELPHelus PharmaSCHEDULE 13GPassive >5% holder (13G)
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte Biosciences10-QQuarterly report
- FBIOFortress BiotechReleaseJourney Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- EYPTEyePointSCHEDULE 13GPassive >5% holder (13G)
- EXELExelixisSCHEDULE 13G/A13G amendment
- ENTXEntera BioDForm D (exempt offering)
- ENTAEnanta Pharmaceuticals10-QQuarterly report
- ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updatevia aggregator
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety DisorderBD extracted 1 program update from this document → DFTX pipeline
- DFTXDefinium Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- CUECue BiopharmaS-3Shelf registration
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CNTBConnect BiopharmaReleaseConnect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
- CNTBConnect Biopharma8-KCurrent report: results of operations · EX-99.1
- CNTBConnect Biopharma10-QQuarterly reportBD extracted 1 program update from this document → CNTB pipeline
- CMMBChemomab TherapeuticsDRSDRS
- CGEMCullinan TherapeuticsReleaseZipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small CellBD extracted 1 program update from this document → CGEM pipeline
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- CABACabaletta BioSCHEDULE 13GPassive >5% holder (13G)
- BLTEBelite BioReleaseBelite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate UpdateBD extracted 1 program update from this document → BLTE pipeline
- BBOTBridgeBio Oncology Therapeutics424B3Prospectus (resale / update)
- APVOAptevo TherapeuticsReleaseAptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
- ANNXAnnexonReleaseAnnexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
- ANNXAnnexonReleaseAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesBD extracted 3 program updates from this document → ANNX pipeline
- ANNXAnnexon8-KCurrent report: results of operations, other events · EX-99.1BD extracted 1 program update from this document → ANNX pipeline
- ANNXAnnexon10-QQuarterly report
- ALTAltimmuneReleaseAltimmune Announces Second Quarter 2026 Financial Results and Business Update
- ALTAltimmune8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → ALT pipeline
- ALTAltimmune10-QQuarterly report
- ALLOAllogene TherapeuticsS-3Shelf registration
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
- ALLOAllogene Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → ALLO pipeline
- ALLOAllogene Therapeutics10-QQuarterly report
- ALDXAldeyra TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ADAGAdageneReleaseAdagene Reports Six Months 2026 Financial Results and Provides Corporate UpdatesBD extracted 2 program updates from this document → ADAG pipeline
- ADAGAdagene6-KForeign issuer report · EX-99.1
- ACRVAcrivon TherapeuticsS-8Employee plan registration
- ACRVAcrivon TherapeuticsReleaseAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
- ACRVAcrivon Therapeutics8-KCurrent report: results of operations · EX-99.1
- ACRVAcrivon Therapeutics10-QQuarterly report
- ABOSAcumen PharmaceuticalsS-8Employee plan registration
- ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
- ABOSAcumen PharmaceuticalsDRSDRS
- ABOSAcumen Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → ABOS pipeline
- ABOSAcumen Pharmaceuticals10-QQuarterly report
Tuesday, August 11103
- ZYMEZymeworksReleaseZymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a port
- ZURAZura BioReleaseZura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
- ZURAZura Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ZURAZura Bio10-QQuarterly report
- WVEWave Life SciencesSCHEDULE 13D/A13D amendment
- VORVor BiopharmaReleaseVor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- VORVor Biopharma10-QQuarterly report
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- TSHATaysha Gene Therapies8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → TSHA pipeline
- TSHATaysha Gene Therapies10-QQuarterly report
- TNGXTango TherapeuticsReleaseTango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsBD extracted 1 program update from this document → TNGX pipeline
- TNGXTango Therapeutics8-KCurrent report: other events
- TNGXTango Therapeutics8-KCurrent report: results of operations · EX-99.1
- TNGXTango Therapeutics424B5Prospectus supplement (offering)
- TNGXTango Therapeutics10-QQuarterly report
- TARAProtara TherapeuticsS-8Employee plan registration
- TARAProtara TherapeuticsReleaseProtara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateBD extracted 1 program update from this document → TARA pipeline
- TARAProtara Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED AUGUST 11, 2026, ISSUED BY THE REGISTRANTBD extracted 1 program update from this document → TARA pipeline
- TARAProtara Therapeutics10-QQuarterly report
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SLSSELLAS Life Sciences Group8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → SLS pipeline
- SLSSELLAS Life Sciences Group10-QQuarterly report
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- SGMTSagimet Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1BD extracted 2 program updates from this document → SGMT pipeline
- SGMTSagimet Biosciences10-QQuarterly report
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypo
- REPLReplimune GroupSCHEDULE 13D/A13D amendment
- REPLReplimune Group8-K/ACurrent report (amended): other events
- RAREUltragenyx Pharmaceutical8-KCurrent report: other events
- PRLDPrelude Therapeutics8-KCurrent report: results of operations · EX-99.1
- PRLDPrelude Therapeutics10-QQuarterly report
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- NGNENeurogeneReleaseNeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updatesvia aggregator
- NGNENeurogene8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → NGNE pipeline
- NGNENeurogene10-QQuarterly report
- MLYSMineralys Therapeutics8-KCurrent report: results of operations, officer / director change · EX-99.1
- MLYSMineralys Therapeutics10-QQuarterly report
- MAZEMaze Therapeutics8-KCurrent report: results of operations · EX-99.1
- MAZEMaze Therapeutics10-QQuarterly report
- LGVNLongeveronReleaseLongeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global CompetitionBD extracted 1 program update from this document → LGVN pipeline
- LENZLENZ TherapeuticsReleaseLENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- LENZLENZ Therapeutics8-KCurrent report: results of operations · EX-99.1
- LENZLENZ Therapeutics10-QQuarterly report
- LEGNLegend BiotechReleaseLegend Biotech Reports Second Quarter 2026 Results and Recent HighlightsBD extracted 2 program updates from this document → LEGN pipeline
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1
- LBRXLB Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- LBRXLB Pharmaceuticals424B3Prospectus (resale / update)
- LBRXLB Pharmaceuticals10-QQuarterly report
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
- KYTXKyverna Therapeutics8-KCurrent report: results of operations · EX-99.1
- KYTXKyverna Therapeutics10-QQuarterly report
- IXHLIncannex HealthcareReleaseIncannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF AUGUST 11, 2026
- IMUXImmunicReleaseImmunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 1 program update from this document → IMUX pipeline
- IMUXImmunic8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1
- IMUXImmunic10-QQuarterly report
- IMNMImmunomeS-8Employee plan registration
- IMNMImmunomeReleaseImmunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateBD extracted 1 program update from this document → IMNM pipeline
- IMNMImmunome8-KCurrent report: results of operations · EX-99.1
- IMNMImmunome10-QQuarterly report
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- GRCEGrace TherapeuticsDForm D (exempt offering)
- GLSIGreenwich LifeSciences10-QQuarterly report
- GANXGain TherapeuticsReleaseGain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate UpdateBD extracted 2 program updates from this document → GANX pipeline
- GANXGain Therapeutics8-KCurrent report: results of operations · EX-99.1
- GANXGain Therapeutics10-QQuarterly report
- FBRXForte BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- ERASErascaS-8Employee plan registration
- ERASErascaReleaseErasca Reports Second Quarter 2026 Business Updates and Financial Results
- ERASErasca8-KCurrent report: results of operations · EX-99.1
- ERASErasca10-QQuarterly report
- ELOXEloxx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → ELOX pipeline
- ELOXEloxx Pharmaceuticals10-QQuarterly report
- EIKNEikon TherapeuticsReleaseEikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
- CRDLCardiol TherapeuticsReleaseInflammation and the Heart: Why the Field Is Asking a Different Question
- COYACoya Therapeutics8-KCurrent report: results of operations · EX-99.1
- COYACoya Therapeutics10-QQuarterly report
- CLNNCleneSCHEDULE 13G/A13G amendment
- CINGCingulateReleaseCingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic ProfileBD extracted 1 program update from this document → CING pipeline
- CCCCC4 TherapeuticsReleaseC4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- CCCCC4 Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → CCCC pipeline
- CCCCC4 Therapeutics10-QQuarterly report
- BLTEBelite BioReleaseBelite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1BD extracted 1 program update from this document → BLTE pipeline
- BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- BCAXBicara TherapeuticsS-8Employee plan registration
- BCAXBicara TherapeuticsReleaseBicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
- BCAXBicara Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → BCAX pipeline
- BCAXBicara Therapeutics10-QQuarterly report
- BBOTBridgeBio Oncology TherapeuticsReleaseBBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
- BBOTBridgeBio Oncology Therapeutics8-KCurrent report: results of operations · EX-99.1
- BBOTBridgeBio Oncology Therapeutics10-QQuarterly report
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATES
- AUTLAutolus Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- AUTLAutolus Therapeutics10-QQuarterly report
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- ATAIAtai Beckley10-QQuarterly report
- ARDXArdelyxSCHEDULE 13G/A13G amendment
- APGEApogee Therapeutics8-KCurrent report: officer / director change, shareholder vote
- ANTXAN2 Therapeutics8-KCurrent report: results of operations · EX-99.1
- ANTXAN2 Therapeutics10-QQuarterly report
- ANABAnaptysBio8-KCurrent report: shareholder vote
- ACIUAC ImmuneReleaseAC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
- ACIUAC Immune6-KForeign issuer report · EX-99.1
- ACHVAchieve Life SciencesReleaseAchieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- ACHVAchieve Life Sciences8-KCurrent report: results of operations · EX-99.1
- ACHVAchieve Life Sciences10-QQuarterly report
- ABSIAbsciReleaseAbsci Reports Business Updates and Second Quarter 2026 Financial and Operating Resultsvia aggregator
- ABSIAbsci8-KCurrent report: results of operations, other events · EX-99.1BD extracted 1 program update from this document → ABSI pipeline
- ABSIAbsci10-QQuarterly report
- AARDAardvark Therapeutics8-KCurrent report: results of operations · EX-99.1
- AARDAardvark Therapeutics10-QQuarterly report
Monday, August 1089
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesS-8 POSEmployee plan registration (post-effective)
- WVEWave Life SciencesReleaseWave Life Sciences Announces Completion of Redomiciliation to Delaware
- WVEWave Life SciencesPOSASRPOSASR
- WVEWave Life SciencesPOS AMPost-effective amendment
- WVEWave Life Sciences15-12G15-12G
- VERAVera TherapeuticsReleaseVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
- VERAVera Therapeutics8-KCurrent report: results of operations · EX-99.1
- VERAVera Therapeutics10-QQuarterly report
- TENXTenax TherapeuticsReleaseTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
- TENXTenax Therapeutics8-KCurrent report: other events · EX-99.1
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis SuppurativaBD extracted 1 program update from this document → SYRE pipeline
- SIONSionna TherapeuticsReleaseSionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
- SIONSionna Therapeutics8-KCurrent report: other events · EX-99.1BD extracted 2 program updates from this document → SION pipeline
- SEPNSepterna8-KCurrent report: results of operations · EX-99.1
- SEPNSepterna10-QQuarterly report
- SCYXScynexisS-8Employee plan registration
- SCYXScynexisReleaseSCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Updatevia aggregatorBD extracted 1 program update from this document → SCYX pipeline
- SCYXScynexis10-QQuarterly reportBD extracted 1 program update from this document → SCYX pipeline
- SANASana BiotechnologyReleaseSana Biotechnology Reports Second Quarter 2026 Financial Results and Business UpdatesBD extracted 2 program updates from this document → SANA pipeline
- SANASana Biotechnology8-KCurrent report: results of operations · EX-99.1
- SANASana Biotechnology10-QQuarterly report
- SABSSAB BiotherapeuticsSCHEDULE 13D/A13D amendment
- RLAYRelay TherapeuticsSCHEDULE 13G/A13G amendment
- REPLReplimune GroupSCHEDULE 13GPassive >5% holder (13G)
- REPLReplimune GroupReleaseReplimune Announces Pricing of $150 Million Underwritten Offering
- REPLReplimune Group8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- REPLReplimune Group424B5Prospectus supplement (offering)
- RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
- RCKTRocket Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- RCKTRocket Pharmaceuticals10-QQuarterly report
- PALIPalisade BioReleasePalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentBD extracted 1 program update from this document → PALI pipeline
- PALIPalisade Bio8-KCurrent report: results of operations · EX-99.1
- PALIPalisade Bio10-QQuarterly report
- ORKAOruka TherapeuticsReleaseOruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 3 program updates from this document → ORKA pipeline
- ORKAOruka Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED AUGUST 10, 2026
- ORKAOruka Therapeutics10-QQuarterly report
- OMEROmerosReleaseOmeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
- OLMAOlema Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- OLMAOlema Pharmaceuticals10-QQuarterly report
- OKUROnKure TherapeuticsSCHEDULE 13G/A13G amendment
- OCSOculis HoldingReleaseOculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology CompanyBD extracted 1 program update from this document → OCS pipeline
- OCSOculis Holding6-KForeign issuer report · EX-99.1
- NKTXNkartaReleaseNkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
- NKTXNkarta8-KCurrent report: results of operations · EX-99.1
- NKTXNkarta10-QQuarterly report
- MLTXMoonLake ImmunotherapeuticsS-8Employee plan registration
- MLTXMoonLake ImmunotherapeuticsS-3ASRAutomatic shelf registration
- MLTXMoonLake ImmunotherapeuticsReleaseMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Secondvia aggregatorBD extracted 1 program update from this document → MLTX pipeline
- MLTXMoonLake ImmunotherapeuticsReleaseMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second
- MLTXMoonLake Immunotherapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED AUGUST 10, 2026BD extracted 1 program update from this document → MLTX pipeline
- MLTXMoonLake Immunotherapeutics10-QQuarterly report
- MBRXMoleculin BiotechSCHEDULE 13GPassive >5% holder (13G)
- MAIAMAIA Biotechnology10-QQuarterly report
- LGVNLongeveronSCHEDULE 13GPassive >5% holder (13G)
- KURAKura OncologyReleaseKura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
- KPRXKiora PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- KODKodiak SciencesReleaseKodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
- JBIOJade BiosciencesReleaseAUGUST 10, 2026 Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- JBIOJade Biosciences8-KCurrent report: results of operations · EX-99.1BD extracted 2 program updates from this document → JBIO pipeline
- JBIOJade Biosciences10-QQuarterly report
- IMUXImmunicReleaseImmunic Appoints Elena Ridloff to Board of Directors
- IBRXImmunityBioReleaseImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
- HROWHarrow8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- HROWHarrow10-QQuarterly report
- HELPHelus PharmaReleaseHelus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
- GUTSFractyl HealthReleaseFractyl Health Reports Second Quarter 2026 Financial Results and Business UpdatesBD extracted 1 program update from this document → GUTS pipeline
- GUTSFractyl Health8-KCurrent report: results of operations · EX-99.1
- GUTSFractyl Health10-QQuarterly report
- GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
- ERASErascaReleaseErasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
- ERASErasca8-KCurrent report: officer / director change
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
- ENTAEnanta Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ELTXElicio TherapeuticsReleaseElicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
- EIKNEikon TherapeuticsReleaseEikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026BD extracted 2 program updates from this document → DRTS pipeline
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED AUGUST 10, 2026
- CRVOCervoMedReleaseCervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesBD extracted 1 program update from this document → CRVO pipeline
- CRVOCervoMed8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
- COGTCogent BiosciencesReleaseCogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → COGT pipeline
- COGTCogent Biosciences8-KCurrent report: other events
- COGTCogent Biosciences8-KCurrent report: results of operations · EX-99.1
- COGTCogent Biosciences424B5Prospectus supplement (offering)
- COGTCogent Biosciences10-QQuarterly report
- CMMBChemomab TherapeuticsSCHEDULE 13G/A13G amendment
- CLNNCleneReleaseClene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
- CLNNClene8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CLNN pipeline
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 ResultsBD extracted 2 program updates from this document → CATX pipeline
- CATXPerspective Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- CATXPerspective Therapeutics10-QQuarterly report
- CAPRCapricor TherapeuticsReleaseCapricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
- AXSMAxsome Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- AXSMAxsome Therapeutics10-QQuarterly report
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATAIAtai BeckleyDEFM14AMerger proxy
- ARTVArtiva BiotherapeuticsSCHEDULE 13G/A13G amendment
- ARDXArdelyxS-8Employee plan registration
- APGEApogee TherapeuticsReleaseApogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline UpdatesBD extracted 1 program update from this document → APGE pipelinecompany site may be offline after the acquisition; linked to the SEC copy · original
- APGEApogee Therapeutics8-KCurrent report: results of operations · EX-99.1
- APGEApogee Therapeutics10-QQuarterly report
- ANNXAnnexonReleaseAnnexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
- ANNXAnnexon8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- AGMBAgomab TherapeuticsReleaseAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
- AGMBAgomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
Friday, August 722
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- WVEWave Life Sciences8-K12B8-K12B
- VSTMVerastemSCHEDULE 13GPassive >5% holder (13G)
- VSTMVerastem8-KCurrent report: material agreement, debt / obligation, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VIRVir BiotechnologySCHEDULE 13GPassive >5% holder (13G)
- VERAVera TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TVTXTravere TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TNGXTango Therapeutics8-K/ACurrent report (amended): officer / director change, Reg FD disclosure · EX-99.1
- SRPTSarepta TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- SNDXSyndax PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- SLSSELLAS Life Sciences GroupSCHEDULE 13GPassive >5% holder (13G)
- RXRXRecursion PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- RLAYRelay TherapeuticsSCHEDULE 13G/A13G amendment
- REPLReplimune GroupSCHEDULE 13GPassive >5% holder (13G)
- REPLReplimune Group8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- RCUSArcus BiosciencesSCHEDULE 13D/A13D amendment
- RAREUltragenyx PharmaceuticalSCHEDULE 13GPassive >5% holder (13G)
- QNRXQuoin PharmaceuticalsReleaseCorporate Overview
- QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
- PTGXProtagonist TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- OCGNOcugenSCHEDULE 13GPassive >5% holder (13G)
- NTLAIntellia TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
- NRXPNRX PharmaceuticalsReleaseFDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for ApprovalBD extracted 1 program update from this document → NRXP pipeline
- NRXPNRX Pharmaceuticals8-KCurrent report: Reg FD disclosure
- MISTMilestone PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- LXEOLexeo TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- KTTAPasithea TherapeuticsDEF 14AProxy statement
- KTTAPasithea TherapeuticsARSAnnual report to shareholders
- KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- KPRXKiora Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- KPRXKiora Pharmaceuticals10-QQuarterly report
- IRDOpus GeneticsS-3Shelf registration
- INABIN8bioS-8Employee plan registration
- IMMXImmix Biopharma10-QQuarterly report
- GRCEGrace TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- GERNGeronSCHEDULE 13GPassive >5% holder (13G)
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- ENTXEntera BioS-8Employee plan registration
- ENTXEntera BioReleaseEntera Announces Second Quarter 2026 Financial Results and Business UpdatesBD extracted 4 program updates from this document → ENTX pipeline
- ENTXEntera Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- ENTXEntera Bio10-QQuarterly report
- DTILPrecision BiosciencesS-8Employee plan registration
- CTMXCytomX TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CRVSCorvus PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- CRVOCervoMedS-8Employee plan registration
- CRVOCervoMed10-QQuarterly report
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- COYACoya Therapeutics8-K/ACurrent report (amended): officer / director change
- CMPXCompass TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CGTXCognition Therapeutics10-QQuarterly report
- CGEMCullinan TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CATXPerspective TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CAPRCapricor TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- BCRXBiocryst PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ANNXAnnexonSCHEDULE 13GPassive >5% holder (13G)
- ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ADMAAdma BiologicsSCHEDULE 13GPassive >5% holder (13G)
Thursday, August 6178
- ZYMEZymeworksReleaseZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsvia aggregator
- ZYMEZymeworks8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1BD extracted 2 program updates from this document → ZYME pipeline
- ZYMEZymeworks10-QQuarterly report
- ZNTLZentalis Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ZNTLZentalis Pharmaceuticals10-QQuarterly report
- XFORX4 Pharmaceuticals10-QQuarterly report
- XERSXeris BiopharmaReleaseXeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
- XERSXeris BiopharmaReleaseXeris Biopharma Reports Second Quarter 2026 Financial Results
- XERSXeris Biopharma8-KCurrent report: results of operations · EX-99.1
- XERSXeris Biopharma10-QQuarterly report
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsReleaseXenon Reports Q2 2026 Financial Results and Provides Business Update
- XENEXenon Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- XENEXenon Pharmaceuticals10-QQuarterly reportBD extracted 1 program update from this document → XENE pipeline
- VYGRVoyager TherapeuticsReleaseVoyager Reports Second Quarter 2026 Financial and Operating Results
- VYGRVoyager Therapeutics8-KCurrent report: results of operations · EX-99.1
- VYGRVoyager Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → VYGR pipeline
- VTVTvTv TherapeuticsReleasevTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- VTVTvTv Therapeutics8-KCurrent report: results of operations · EX-99.1
- VTVTvTv Therapeutics10-QQuarterly report
- VSTMVerastemReleaseVerastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesBD extracted 2 program updates from this document → VSTM pipeline
- VSTMVerastem8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- VSTMVerastem10-QQuarterly report
- VRDNViridian TherapeuticsReleaseViridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → VRDN pipeline
- VRDNViridian Therapeutics8-KCurrent report: results of operations · EX-99.1
- VRDNViridian Therapeutics10-QQuarterly report
- VRCAVerrica Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- VRCAVerrica Pharmaceuticals10-QQuarterly report
- VORVor BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- VNDAVanda Pharmaceuticals10-QQuarterly report
- TVTXTravere TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsReleaseTango Therapeutics Announces Executive Chair Transition
- TNGXTango Therapeutics8-KCurrent report: officer / director change
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED AUGUST 6, 2026
- TECXTectonic TherapeuticReleaseEnrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results antici
- TECXTectonic Therapeutic8-KCurrent report: results of operations · EX-99.1
- TECXTectonic Therapeutic10-QQuarterly report
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- SLDBSolid BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- SLDBSolid BiosciencesS-3ASRAutomatic shelf registration
- SLDBSolid BiosciencesReleaseSolid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updatesvia aggregator
- SLDBSolid Biosciences8-KCurrent report: other events
- SLDBSolid Biosciences424B5Prospectus supplement (offering)
- SLDBSolid Biosciences10-QQuarterly report
- SIONSionna TherapeuticsReleaseSionna Therapeutics Reports Second Quarter 2026 Financial Results
- SIONSionna Therapeutics8-KCurrent report: results of operations · EX-99.1
- SIONSionna Therapeutics10-QQuarterly report
- SABSSAB BiotherapeuticsReleaseSAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
- SABSSAB Biotherapeutics10-QQuarterly report
- RNACCartesian TherapeuticsReleaseCartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateBD extracted 1 program update from this document → RNAC pipeline
- RNACCartesian Therapeutics8-KCurrent report: results of operations · EX-99.1
- RNACCartesian Therapeutics10-QQuarterly report
- RLMDRelmada TherapeuticsReleaseRelmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- RLMDRelmada Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING IBD extracted 2 program updates from this document → RLMD pipeline
- RLMDRelmada Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → RLMD pipeline
- RLAYRelay TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RLAYRelay Therapeutics8-KCurrent report: material agreement, results of operations · EX-99.1
- RLAYRelay Therapeutics424B5Prospectus supplement (offering)
- RLAYRelay Therapeutics10-QQuarterly report
- REPLReplimune GroupSCHEDULE 13G/A13G amendment
- REPLReplimune GroupReleaseReplimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based RegimenBD extracted 1 program update from this document → REPL pipeline
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
- PHIOPhio Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → PHIO pipeline
- PHIOPhio Pharmaceuticals10-QQuarterly report
- PEPGPepGenReleasePepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Reviewvia aggregatorBD extracted 1 program update from this document → PEPG pipeline
- PEPGPepGenReleasePepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlightsvia aggregator
- PEPGPepGen8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1
- PEPGPepGen10-QQuarterly report
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
- OLMAOlema PharmaceuticalsSCHEDULE 13G/A13G amendment
- OCSOculis HoldingS-8Employee plan registration
- OCSOculis HoldingReleaseOculis Reports Q2 2026 Financial Results and Provides Company UpdateBD extracted 1 program update from this document → OCS pipeline
- OCSOculis Holding6-KForeign issuer report · EX-99.1
- OCGNOcugenReleaseOcugen Provides Business Update with Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → OCGN pipeline
- OCGNOcugen8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- OCGNOcugen10-QQuarterly report
- NVCTNuvectis PharmaSCHEDULE 13GPassive >5% holder (13G)
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesBD extracted 1 program update from this document → NTLA pipeline
- NTLAIntellia Therapeutics8-KCurrent report: results of operations · EX-99.1
- NTLAIntellia Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → NTLA pipeline
- NRSNNeuroSense TherapeuticsReleaseFinal meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd....BD extracted 1 program update from this document → NRSN pipeline
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED AUGUST 6, 2026
- NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
- MLYSMineralys TherapeuticsSCHEDULE 13G/A13G amendment
- MBRXMoleculin BiotechSCHEDULE 13GPassive >5% holder (13G)
- LEGNLegend BiotechSCHEDULE 13G/A13G amendment
- LEGNLegend Biotech6-KForeign issuer report
- LCTXLineage Cell Therapeutics8-KCurrent report: results of operations · EX-99.1
- LCTXLineage Cell Therapeutics10-QQuarterly report
- KODKodiak SciencesReleaseKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Tra
- JANXJanux TherapeuticsReleaseJanux Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsBD extracted 1 program update from this document → JANX pipeline
- JANXJanux Therapeutics8-KCurrent report: results of operations · EX-99.1
- JANXJanux Therapeutics10-QQuarterly report
- IRONDisc MedicineSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsReleaseOpus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate UpdateBD extracted 3 program updates from this document → IRD pipeline
- IRDOpus Genetics8-KCurrent report: results of operations · EX-99.1
- IRDOpus Genetics10-QQuarterly report
- INSMInsmedSCHEDULE 13G/A13G amendment
- INSMInsmed8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- INSMInsmed10-QQuarterly report
- INMBInmune BioReleaseINmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and C...BD extracted 1 program update from this document → INMB pipeline
- INMBInmune Bio10-QQuarterly reportBD extracted 1 program update from this document → INMB pipeline
- INKTMiNK TherapeuticsReleaseMiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
- INKTMiNK TherapeuticsReleaseMiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research SymposiumBD extracted 1 program update from this document → INKT pipeline
- INABIN8bioReleaseIN8bio Reports Second Quarter 2026 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → INAB pipeline
- INABIN8bio8-KCurrent report: results of operations · EX-99.1
- INABIN8bio10-QQuarterly report
- IMVTImmunovantReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026via aggregator
- IMVTImmunovant8-KCurrent report: results of operations · EX-99.1
- IMVTImmunovant10-QQuarterly reportBD extracted 2 program updates from this document → IMVT pipeline
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMCRImmunocoreSCHEDULE 13G/A13G amendment
- IMCRImmunocore8-KCurrent report: results of operations · EX-99.1
- IMCRImmunocore10-QQuarterly report
- IBRXImmunityBioSCHEDULE 13D/A13D amendment
- HROWHarrow8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- GRCEGrace Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1 EXHIBIT 99.1
- GPCRStructure TherapeuticsSCHEDULE 13G/A13G amendment
- GPCRStructure TherapeuticsReleaseStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsBD extracted 1 program update from this document → GPCR pipeline
- GPCRStructure Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- GPCRStructure Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → GPCR pipeline
- GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesBD extracted 2 program updates from this document → GLUE pipeline
- GLUEMonte Rosa Therapeutics8-KCurrent report: results of operations · EX-99.1
- GLUEMonte Rosa Therapeutics10-QQuarterly report
- GHRSGH ResearchReleaseGH Research Reports Second Quarter 2026 Financial Results and Provides Business Updatevia aggregatorBD extracted 1 program update from this document → GHRS pipeline
- GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GERNGeron8-KCurrent report: results of operations · EX-99.1
- FHTXFoghorn TherapeuticsReleaseFilter by Year:
- FHTXFoghorn TherapeuticsReleaseFoghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate UpdateBD extracted 2 program updates from this document → FHTX pipeline
- FHTXFoghorn Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1BD extracted 1 program update from this document → FHTX pipeline
- FHTXFoghorn Therapeutics10-QQuarterly report
- FBRXForte BiosciencesSC TO-T/ASC TO-T/A
- FBRXForte BiosciencesSC TO-TTender offer
- FBRXForte BiosciencesSC 14D9Tender offer response
- FBRXForte BiosciencesReleaseargenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.company site may be offline after the acquisition
- EWTXEdgewise TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- EWTXEdgewise Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- EWTXEdgewise Therapeutics10-QQuarterly report
- EVMNEvommuneReleaseEvommune Reports Second Quarter 2026 Financial Results and Provides Business HighlightsBD extracted 1 program update from this document → EVMN pipeline
- EVMNEvommune8-KCurrent report: results of operations · EX-99.1
- EVMNEvommune424B3Prospectus (resale / update)
- EVMNEvommune10-QQuarterly reportBD extracted 1 program update from this document → EVMN pipeline
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- EIKNEikon TherapeuticsSCHEDULE 13G/A13G amendment
- DYNDyne TherapeuticsSCHEDULE 13G/A13G amendment
- DTILPrecision BiosciencesReleasePrecision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
- DTILPrecision Biosciences8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → DTIL pipeline
- DTILPrecision Biosciences10-QQuarterly report
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsBD extracted 1 program update from this document → DFTX pipeline
- DFTXDefinium Therapeutics8-KCurrent report: results of operations · EX-99.1
- DFTXDefinium Therapeutics10-QQuarterly report
- DBVTDBV TechnologiesSCHEDULE 13GPassive >5% holder (13G)
- CTMXCytomX TherapeuticsS-8Employee plan registration
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
- CTMXCytomX Therapeutics8-KCurrent report: results of operations · EX-99.1
- CTMXCytomX Therapeutics10-QQuarterly report
- CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
- CRVSCorvus Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 PRESS RELEASEBD extracted 1 program update from this document → CRVS pipeline
- CRVSCorvus Pharmaceuticals10-QQuarterly report
- CMPXCompass Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- CMPXCompass Therapeutics10-QQuarterly report
- CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
- CMPSCOMPASS PathwaysReleaseCompass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
- CLYMClimb BioReleaseClimb Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBD extracted 2 program updates from this document → CLYM pipeline
- CLYMClimb Bio8-KCurrent report: results of operations · EX-99.1
- CLYMClimb Bio10-QQuarterly reportBD extracted 1 program update from this document → CLYM pipeline
- CLDXCelldex TherapeuticsReleaseCelldex Reports Second Quarter Financial Results and Provides Corporate Update
- CLDXCelldex Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASEBD extracted 3 program updates from this document → CLDX pipeline
- CLDXCelldex Therapeutics10-QQuarterly report
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
- CGTXCognition Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- CGONCG OncologyReleaseCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBD extracted 1 program update from this document → CGON pipeline
- CGONCG Oncology8-KCurrent report: results of operations, other events · EX-99.1
- CGONCG Oncology424B5Prospectus supplement (offering)
- CGONCG Oncology10-QQuarterly report
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → CGEM pipeline
- CGEMCullinan Therapeutics8-KCurrent report: results of operations · EX-99.1
- CGEMCullinan Therapeutics10-QQuarterly reportBD extracted 1 program update from this document → CGEM pipeline
- BLTEBelite BioReleaseBelite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics to Present at the Canaccord Genuity Growth Conference
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARTVArtiva BiotherapeuticsS-3Shelf registration
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → ARTV pipeline
- ARTVArtiva Biotherapeutics8-KCurrent report: results of operations · EX-99.1
- ARTVArtiva Biotherapeutics10-QQuarterly report
- ARDXArdelyxReleaseArdelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
- ARDXArdelyx8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ARDXArdelyx10-QQuarterly report
- APGEApogee TherapeuticsDEFA14AProxy soliciting material
- ANNXAnnexonReleaseAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
- ANNXAnnexon8-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ANNX pipeline
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Reports Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → AMLX pipeline
- AMLXAmylyx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- AMLXAmylyx Pharmaceuticals10-QQuarterly reportBD extracted 1 program update from this document → AMLX pipeline
- ALDXAldeyra Therapeutics10-QQuarterly report
- AGMBAgomab TherapeuticsReleaseAgomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
- AGMBAgomab Therapeutics6-KForeign issuer report · EX-99.1
- ADCTADC TherapeuticsReleaseADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
- ACRSAclaris TherapeuticsS-3ASRAutomatic shelf registration
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateBD extracted 1 program update from this document → ACRS pipeline
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)BD extracted 1 program update from this document → ACRS pipeline
- ACRSAclaris Therapeutics8-KCurrent report: material agreementBD extracted 1 program update from this document → ACRS pipeline
- ACRSAclaris Therapeutics8-KCurrent report: results of operations · EX-99.1
- ACRSAclaris Therapeutics10-QQuarterly report
Wednesday, August 5101
- XNCRXencorReleaseXencor Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → XNCR pipeline
- XNCRXencor8-KCurrent report: results of operations · EX-99.1
- XNCRXencor10-QQuarterly report
- WVEWave Life SciencesReleaseWave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
- VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
- VNDAVanda Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Pricing of Public Offering of Common Stock
- VIRVir BiotechnologyReleaseVir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Proposed Public Offering of Common Stock
- VIRVir BiotechnologyReleaseVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- VIRVir BiotechnologyReleaseVir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical MilestonesBD extracted 2 program updates from this document → VIR pipeline
- VIRVir BiotechnologyReleaseVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
- VIRVir BiotechnologyReleaseVir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
- VIRVir BiotechnologyReleaseVir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
- VIRVir BiotechnologyReleaseAstellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- VIRVir BiotechnologyReleaseVir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
- VIRVir BiotechnologyReleaseVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsBD extracted 3 program updates from this document → VIR pipeline
- VIRVir Biotechnology8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → VIR pipeline
- VIRVir Biotechnology10-QQuarterly report
- TGTXTg Therapeutics10-QQuarterly report
- SRPTSarepta TherapeuticsReleaseSarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate DevelopmentsBD extracted 2 program updates from this document → SRPT pipeline
- SRPTSarepta Therapeutics8-KCurrent report: results of operations · EX-99.1
- SRPTSarepta Therapeutics10-QQuarterly report
- SMMTSummit TherapeuticsReleaseSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
- SMMTSummit Therapeutics8-KCurrent report: other events · EX-99.1
- RXRXRecursion Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- RXRXRecursion Pharmaceuticals10-QQuarterly report
- RVMDRevolution Medicines8-KCurrent report: results of operations · EX-99.1
- RVMDRevolution Medicines10-QQuarterly report
- RCUSArcus BiosciencesReleaseArcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a P...BD extracted 1 program update from this document → RCUS pipeline
- RCUSArcus Biosciences8-KCurrent report: results of operations · EX-99.1BD extracted 2 program updates from this document → RCUS pipeline
- RCUSArcus Biosciences10-QQuarterly report
- RAREUltragenyx Pharmaceutical10-QQuarterly report
- RAPPRapport Therapeutics8-KCurrent report: results of operations · EX-99.1
- RAPPRapport Therapeutics10-QQuarterly report
- QTTBQ32 Bio8-KCurrent report: results of operations · EX-99.1
- QTTBQ32 Bio10-QQuarterly report
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8 POSEmployee plan registration (post-effective)
- PTGXProtagonist TherapeuticsS-8Employee plan registration
- PTGXProtagonist Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- PTGXProtagonist Therapeutics10-QQuarterly report
- PCVXVaxcyteReleaseVaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
- PCVXVaxcyte8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → PCVX pipeline
- PCVXVaxcyte10-QQuarterly reportBD extracted 1 program update from this document → PCVX pipeline
- NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial ResultsBD extracted 2 program updates from this document → NAMS pipeline
- NAMSNewAmsterdam Pharma8-KCurrent report: results of operations · EX-99.1
- NAMSNewAmsterdam Pharma10-QQuarterly report
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathycompany site may be offline after the acquisition
- KYMRKymera TherapeuticsReleaseEnrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate bBD extracted 1 program update from this document → KYMR pipeline
- KYMRKymera Therapeutics8-KCurrent report: results of operations · EX-99.1
- KYMRKymera Therapeutics10-QQuarterly report
- KURAKura OncologyReleaseKura Oncology to Report Second Quarter Financial Results
- IMRXImmuneeringReleaseImmuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
- IMRXImmuneering8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → IMRX pipeline
- IMRXImmuneering10-QQuarterly report
- GERNGeronS-8Employee plan registration
- GERNGeronReleaseGeron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- GERNGeron10-QQuarterly report
- FBIOFortress BiotechReleaseJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
- EYPTEyePointS-8Employee plan registration
- EYPTEyePointReleaseEyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
- EYPTEyePoint8-KCurrent report: results of operations · EX-99.1
- EYPTEyePoint10-QQuarterly report
- EXELExelixisS-8Employee plan registration
- EXELExelixisReleaseExelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- EXELExelixis8-KCurrent report: results of operations · EX-99.1BD extracted 2 program updates from this document → EXEL pipeline
- EXELExelixis10-QQuarterly report
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001BD extracted 2 program updates from this document → ETON pipeline
- ETONEton Pharmaceuticals8-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ASN-001BD extracted 1 program update from this document → ETON pipeline
- ELVNEnliven Therapeutics8-KCurrent report: results of operations · EX-99.1
- ELVNEnliven Therapeutics10-QQuarterly report
- CRVOCervoMedReleaseCervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
- CRDLCardiol TherapeuticsReleaseCardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 46th Annual Growth Conference
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED AUGUST 5, 2026
- CMPSCOMPASS PathwaysS-3ASRAutomatic shelf registration
- CMPSCOMPASS PathwaysReleaseCompass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
- CMPSCOMPASS Pathways8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → CMPS pipeline
- CMPSCOMPASS Pathways10-QQuarterly report
- CHRSCoherus OncologyS-8Employee plan registration
- CHRSCoherus OncologyReleasePrint Page
- CHRSCoherus OncologyReleaseCoherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
- CHRSCoherus Oncology8-KCurrent report: results of operations · EX-99.1
- CHRSCoherus Oncology10-QQuarterly report
- BMEABiomea FusionReleaseBiomea Fusion Reports Second Quarter 2026 Financial Results and Corporate HighlightsBD extracted 1 program update from this document → BMEA pipeline
- BMEABiomea Fusion8-KCurrent report · EX-99.1
- BMEABiomea Fusion10-QQuarterly reportBD extracted 1 program update from this document → BMEA pipeline
- BIOABioAge LabsReleaseBioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
- BIOABioAge Labs8-KCurrent report: results of operations · EX-99.1
- BIOABioAge Labs10-QQuarterly report
- BDTXBlack Diamond Therapeutics8-KCurrent report: results of operations · EX-99.1
- BDTXBlack Diamond Therapeutics10-QQuarterly report
- BCRXBiocryst PharmaceuticalsS-8Employee plan registration
- BCRXBiocryst Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE
- BCRXBiocryst Pharmaceuticals10-QQuarterly report
- ALTAltimmuneReleaseAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
- AKBAAkebia TherapeuticsS-8Employee plan registration
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- AKBAAkebia Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → AKBA pipeline
- AKBAAkebia Therapeutics10-QQuarterly report
- ADMAAdma BiologicsReleaseADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
- ADMAAdma Biologics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- ADMAAdma Biologics10-QQuarterly report
- ACRVAcrivon TherapeuticsReleaseAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyBD extracted 2 program updates from this document → ACRV pipeline
- ACIUAC ImmuneReleaseAC Immune First Half 2026 Financial and Corporate UpdateBD extracted 2 program updates from this document → ACIU pipeline
- ACIUAC Immune6-KForeign issuer report · EX-99.1
- ACETAdicet Bio8-KCurrent report: results of operations · EX-99.1
- ACETAdicet Bio10-QQuarterly report
- ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
Tuesday, August 459
- TYRATyra BiosciencesReleaseTyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
- TYRATyra Biosciences8-KCurrent report: results of operations · EX-99.1
- TYRATyra Biosciences424B5Prospectus supplement (offering)
- TYRATyra Biosciences10-QQuarterly report
- TVTXTravere TherapeuticsReleaseTravere Therapeutics Reports Second Quarter 2026 Financial ResultsBD extracted 1 program update from this document → TVTX pipeline
- TVTXTravere Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → TVTX pipeline
- TVTXTravere Therapeutics10-QQuarterly report
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED AUGUST 4, 2026
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SYRESpyre Therapeutics8-KCurrent report: results of operations · EX-99.1BD extracted 2 program updates from this document → SYRE pipeline
- SYRESpyre Therapeutics10-QQuarterly report
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SNDXSyndax Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- SNDXSyndax Pharmaceuticals10-QQuarterly report
- SGMTSagimet BiosciencesReleaseSagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
- RYTMRhythm Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1BD extracted 4 program updates from this document → RYTM pipeline
- RYTMRhythm Pharmaceuticals10-QQuarterly report
- RAREUltragenyx PharmaceuticalReleaseUltragenyx Reports Second Quarter 2026 Financial Results and Corporate UpdateBD extracted 1 program update from this document → RARE pipeline
- RAREUltragenyx Pharmaceutical8-KCurrent report: results of operations · EX-99.1
- PCSAProcessa Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- OKUROnKure Therapeutics8-KCurrent report: results of operations · EX-99.1
- OKUROnKure Therapeutics424B5Prospectus supplement (offering)
- OKUROnKure Therapeutics10-QQuarterly report
- NVCTNuvectis PharmaReleaseNuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlightsvia aggregatorBD extracted 1 program update from this document → NVCT pipeline
- NVCTNuvectis Pharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- NVCTNuvectis Pharma10-QQuarterly reportBD extracted 1 program update from this document → NVCT pipeline
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaBD extracted 1 program update from this document → NRIX pipeline
- NRIXNurix TherapeuticsReleaseNurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 DegraderBD extracted 1 program update from this document → NRIX pipeline
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Reports Second Quarter 2026 Financial and Business UpdateBD extracted 1 program update from this document → LRMR pipeline
- LRMRLarimar Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- LRMRLarimar Therapeutics10-QQuarterly report
- LQDALiquidiaSCHEDULE 13G/A13G amendment
- LENZLENZ TherapeuticsReleaseLENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
- IMUXImmunicSCHEDULE 13GPassive >5% holder (13G)
- IMMXImmix BiopharmaReleaseImmix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- IDYAIDEAYA Biosciences8-KCurrent report: results of operations · EX-99.1
- IDYAIDEAYA Biosciences10-QQuarterly report
- IBRXImmunityBioReleaseImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
- IBRXImmunityBio8-KCurrent report: results of operations · EX-99.1
- IBRXImmunityBio10-QQuarterly report
- HRMYHarmony Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- HRMYHarmony Biosciences10-QQuarterly report
- GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces $10 Million Private Placement
- ETONEton Pharmaceuticals8-KCurrent report: officer / director change
- ENTXEntera BioSCHEDULE 13GPassive >5% holder (13G)
- ENTXEntera BioSCHEDULE 13GPassive >5% holder (13G)
- ENTXEntera BioSCHEDULE 13GPassive >5% holder (13G)
- ENTXEntera BioSCHEDULE 13GPassive >5% holder (13G)
- ENTXEntera BioSCHEDULE 13DActivist / >5% holder (13D)
- ENTXEntera BioReleaseEntera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at theBD extracted 1 program update from this document → ENTX pipeline
- CRVOCervoMedReleaseCervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
- CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CLNNCleneSCHEDULE 13GPassive >5% holder (13G)
- CGENCompugenUPLOADUPLOAD
- BEAMBeam TherapeuticsReleaseBeam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)BD extracted 2 program updates from this document → BEAM pipeline
- BEAMBeam Therapeutics8-KCurrent report: results of operations · EX-99.1
- BEAMBeam Therapeutics10-QQuarterly report
- BCRXBiocryst Pharmaceuticals8-K/ACurrent report (amended): exit / restructuring costs
- BCAXBicara TherapeuticsReleaseBicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARVNArvinasReleaseArvinas Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBD extracted 2 program updates from this document → ARVN pipeline
- ARVNArvinas8-KCurrent report: results of operations · EX-99.1
- ARVNArvinas10-QQuarterly report
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Monday, August 348
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
- TGTXTg TherapeuticsReleaseTG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue GuidanceBD extracted 1 program update from this document → TGTX pipeline
- TGTXTg Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- STOKStoke TherapeuticsS-8Employee plan registration
- STOKStoke Therapeutics8-KCurrent report: other events
- STOKStoke Therapeutics8-KCurrent report: results of operations · EX-99.1
- STOKStoke Therapeutics424B5Prospectus supplement (offering)
- STOKStoke Therapeutics10-QQuarterly report
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
- RVPHReviva PharmaceuticalsSCHEDULE 13G/A13G amendment
- RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon DiseaseBD extracted 1 program update from this document → RCKT pipeline
- RCKTRocket Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- PTNPalatin Technologies8-KCurrent report: shareholder vote
- PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
- ORICOric Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ORICOric Pharmaceuticals10-QQuarterly report
- OMEROmerosReleaseCMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
- OCSOculis HoldingReleaseOculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
- MPLTMapLight TherapeuticsSCHEDULE 13D/A13D amendment
- MBRXMoleculin Biotech8-KCurrent report: material agreement
- MBRXMoleculin Biotech424B5Prospectus supplement (offering)
- LGVNLongeveronReleaseLongeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
- KROSKeros Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
- KROSKeros Therapeutics8-KCurrent report: results of operations · EX-99.1
- KROSKeros Therapeutics10-QQuarterly report
- IRDOpus GeneticsReleaseOpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseBD extracted 1 program update from this document → IRD pipeline
- INBXInhibrx BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- HELPHelus PharmaReleaseHelus Pharma Appoints Michael Halstead as Chief Executive Officer
- HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GUTSFractyl HealthReleaseFractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026via aggregator
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
- EIKNEikon Therapeutics8-KCurrent report: officer / director change
- CUECue BiopharmaReleaseCue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug SubmissionBD extracted 1 program update from this document → CUE pipeline
- CUECue Biopharma8-KCurrent report: officer / director change
- CTMXCytomX TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRNXCrinetics PharmaceuticalsReleaseCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateBD extracted 1 program update from this document → CRNX pipelinecompany site may be offline after the acquisition; linked to the SEC copy · original
- CRNXCrinetics Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- CRNXCrinetics Pharmaceuticals10-QQuarterly report
- CGENCompugenReleaseCompugen Reports Second Quarter 2026 Results
- CGENCompugen6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CGENCompugen6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1
- CAPRCapricor TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS REPORTS PRELIMINARY SECOND QUARTER 2026 NET PRODUCT REVENUE AND ANNOUNCES CREDIT FACILITY OF UP TO $250 MILLION WITH PERCEPTIVE ADVISORS
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 11, 2026
- AUTLAutolus Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- AUTLAutolus Therapeutics8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity
- ARTVArtiva BiotherapeuticsDEF 14AProxy statement
- ARTVArtiva BiotherapeuticsARSAnnual report to shareholders
- APGEApogee TherapeuticsDEFA14AProxy soliciting material
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
- ALTAltimmuneReleaseAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHBD extracted 1 program update from this document → ALT pipeline
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
- AGIOAgios PharmaceuticalsSCHEDULE 13G/A13G amendment
Saturday, August 11
- DTILPrecision BiosciencesReleasehttps://www.businesswire.com/news/home/20260727263231/en/